Zoryve is also available in a 0.3% cream formulation for the treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.

Guselkumab was an effective treatment for plaque psoriasis with extensive body involvement among patients with skin of color.

Scalp psoriasis is a chronic, non-contagious skin condition that appears as red, itchy, scaly patches on the scalp. Some notice dandruff-like flaking, itching, burning sensations, bleeding or ...

“Up to 80% of patients with plaque psoriasis experience scalp psoriasis, making it one of the most affected areas of the body,” said Philip M. Brown, MD, JD, Chief Medical Officer at Dermavant.

At Week 16, nearly 7 in 10 patients receiving TREMFYA achieved the study’s co-primary endpoints, Scalp-Specific Investigator Global Assessment (ss-IGA) score of 0/1 (68.4% vs 11.5% placebo) and ...

In the study, TREMFYA demonstrated significant skin clearance, rapid scalp psoriasis clearance, and improved health-related quality of life outcomes.

In the study, 154 patients with scalp psoriasis were randomly assigned deucravacitinib (n = 103) or placebo (n = 51). Results showed that 48.5% of deucravacitinib-treated patients achieved a scalp ...

In two studies of people with moderate to severe plaque psoriasis including 1,684 adults, 841 people received Sotyktu, 422 received another medicine called Otezla® (apremilast), and 421 received ...